Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.
Last trade$21.78
Day change-$0.08 (-0.37%)
Day range$21.75 – $21.94
Volume600,468
Market cap$11.35B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for FMS.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for FMS, quarterly periods
Line item
Q4 FY2014 Dec 31, 2014
Q4 FY2013 Dec 31, 2013
Q4 FY2012 Dec 31, 2012
Q4 FY2011 Dec 31, 2011
Q4 FY2010 Dec 31, 2010
Revenue
—
—
—
—
—
Cost of revenue
$0
$0
$0
$0
$0
Gross profit
—
—
—
—
—
Selling, general and administrative
—
—
—
—
—
Research and development
—
—
—
—
—
Total operating expenses
—
—
—
—
—
Operating income
—
—
—
—
—
Interest expense
—
—
—
—
—
Income before taxes
—
—
—
—
—
Income taxes
—
—
—
—
—
Net income
—
—
—
—
—
Net income attributable to common shareholders
—
—
—
—
—
EBITDA
$0
$0
$0
$0
$0
Basic earnings per share
—
—
—
—
—
Diluted earnings per share
—
—
—
—
—
Recent news
Company coverage with links to the original publishers.
The global dialysis machines market is projected to grow from USD 17.89 billion in 2026 to USD 31.54 billion by 2035, driven by rising chronic kidney disease prevalence, expanding home-based treatment options, and technological advancements. North America leads with 40% market share, while Asia Pacific shows fastest growth. Hemodialysis machines dominate at 60% of product revenue, with peritoneal dialysis and artificial kidney technologies emerging as key growth areas.
Fresenius Medical Care (FMS) announced the U.S. launch of its FDA-cleared multiFiltratePRO System for treating acute kidney injury in critically ill patients. The integrated continuous kidney replacement therapy system automates regional citrate anticoagulation procedures in ICUs. FMS stock gained 3.1% following the announcement. The company plans a phased U.S. rollout targeting growth in the hospital-based acute kidney care market, with the global CRRT market expected to grow at 8.2% CAGR through 2034.
Fresenius Medical Care (FMS) is improving profitability through its FME25+ transformation program and showing promise with 5008X dialysis system adoption and value-based care expansion. However, the company faces significant headwinds including U.S. treatment volume weakness, TDAPA reimbursement reversals expected to create a €50 million headwind in 2026, China regulatory pressure, and inflation concerns. The company maintains a Zacks Rank #3 (Hold) rating with consensus expectations for 2.7% revenue growth but 5.4% earnings decline in 2026.
Fresenius Medical Care is scaling up its 5008X CAREsystem rollout, converting 227 U.S. clinics to the new technology by July 2026, representing 10% of its machine base. The company has performed over 600,000 treatments including 100,000+ high-volume hemodiafiltration treatments, showing clinical promise with 40% fewer muscle cramps. However, near-term headwinds include weak U.S. treatment volume growth (-0.9%), TDAPA reimbursement pressure (€50 million drag expected), and significant rollout implementation costs.
Fresenius Medical Care (FMS) is improving profitability through its FME25+ transformation program and expanding high-volume HDF and 5008X dialysis systems. However, the company faces significant challenges including persistent U.S. treatment volume weakness, TDAPA reimbursement reversals expected to create a €50 million headwind in 2026, China regulatory pressure, and inflation-related cost risks. The company maintains a Zacks Rank #3 (Hold) with consensus 2026 earnings expected to decline 7% year-over-year.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
May 22, 2026
$0.8643
Jun 8, 2026
recurring
May 23, 2025
$0.815
Jun 6, 2025
recurring
May 17, 2024
$0.6428
Jun 3, 2024
recurring
May 17, 2023
$0.6049
Jun 1, 2023
recurring
May 13, 2022
$0.7085
May 27, 2022
recurring
Stock splits
Historical share-structure events and their execution dates.